【4565】そーせいG 439 【3月14日SOSEI個人投資家説明会】
■ このスレッドは過去ログ倉庫に格納されています
>>83
個人ホルダーは怒ってたけど株価は上がっていったじゃん
いつも投げさせられるのは個人なのだ 俺は当時売り煽り共にのせられてペプチを疑ってしまったがリリー（だったかな？）の契約に目を冷まして少ないながら飛び込んだよｗ >>82
あれを信じろと言う方がおかしいだろw
大体ドリームっていう名前も不審がられてたろ
夢のつく会社ってロクなのほとんどないからな それでも出すと出さないとでは大違い
その後も悪材料の度にフォーローのIR入れてるしそういう姿勢が評価されてるんだと思うよ ペプチはクソ決算売り気配で始まってもファンドらしき大量の買いがしっかり入るからな 次なる飛躍へ。着実な進捗と共に更なる成長の黎明期にて振るい育ちゆく相場。控える材料と共に水準訂正。笑。
成長期。予定されていた業績の急成長と共に更なる成長戦略が進展。順調なR&D・PL等の拡充・拡大の加速。笑。
Heptares is Currently Based in Welwyn Garden City but will be Moving to a brand New Research Facility at Granta Park (Cambridge) in July 2018.
Heptares has been Operating Approximately 130 Employees who will all be based in this New Research Facility.
・・・
※Heptares: Overview September: ttps://www.heptares.com/uploads/Heptares%20Corporate%202017%20-%20Sep.pdf (9/27update) ※Heptares_HP_Pipeline: M1 Status. (9/28Change)
・M1 Agonist - HTL009936/HTL0018318: First-In-Class Oral Agents in Phase 1 Clinical Studies. "Planning Underway for Studies in AD Patients"
・M4 Agonist - HTL0016878 - Highly Selective for M4, optimised pharmacology: Phase 1 Study Initiated in Healthy Subjects.
・Dual M1/M4 agonists - Cognitive impairment & neurobehavioural symptoms: In Preclinical Stage.
・Wave 1 Partnered Pipeline: M1, Progression 2017-2019: "Start of Phase 2 POC Trial in AD Patients", "AD PoC Results Emerging"
・Wave 1 Partnered Pipeline: M4, Progression 2017-2019: "Start of Phase 1 Trial", "Phase 1 Results", "Progression to PoC Studies"
・Wave 1 Partnered Pipeline: M1M4 dual, Progression 2017-2019: "Start of Phase 1 Trial"
※大阪大学：これまで認知症診療や臨床研究の実績のある大阪大学において、認知症に対する高度な専門医療を実践するとともに、認知症医療イニシアチブが始動！ヘプタレス社 寄附講座設置。(10/18)
※ClinicalTrials: A FDG-PET Study of AGN-242071 Added to Standard-of-Care (Donepezil±Memantine) for the Treatment of Participants With Mild to Moderate Alzheimer's Disease: New Trial Record. Ph1b. (10/21up)
※Allergan Q3 2017: Pipeline Highlights 2017: Muscarinic Receptor M1: Ph 1, 2H 2017 and M4 Agonist: Entry Ph 1, 2H 2017. Rspectively: "Achieved" (11/1)
※SOSEI：レビー小体型認知症患者を対象とするHTL0018318の日本臨床開発開始。提携契約を主要な認知症を追加承認取得する改定。研究開発協力分野を拡大。2018年にPh2 POC試験開始予定。(11/9)
※SOSEI第2四半期決算：研究開発費(94.6％は英国)増加。開発促進のための臨床開発並びにトランスレーショナル医療の拡大・拡張へ向けた取組み。毎年平均3品目化合物を臨床入り。(11/9)
※SOSEI第2四半期決算説明会：パイプライン開発進捗状況：(11/9) ・説明会(音声)：ttp://www.c-hotline.net/Viewer/Default/SOSEf56638580e1f151454e3fdc7e407ca64：Q&A, HTL009936. (11/14up)
・M1 AD：アルツハイマー型認知症患者を対象にした選択的M1受容体作動薬のPh1bを開始。HTL0018318は他の物質候補群に比べて良好なプロファイル。(New)
・M4 SZ：ファースト・イン・クラスの選択的M4受容体作動薬であるHTL0016878のPh1において健康人への初投与を実施。マイルストン収入15百万ドルを受領。(9/1)
・M1 DLB：日本におけるDLB開発・販売権を獲得。2018年中にPh2a POC試験(単剤投与)を開始予定。日本国内における製造販売承認申請並びに上市を目指す。(New) ※ClinicalTrials: FDG-PET Study of AGN-242071 Added to Standard-of-Care (Donepezil ± Memantine): Changed, Start: 2017/11/28→"2018/2/20", Changed, Completion Date: 2018/6/4→"2018/11/4". (1/12update)
※SOSEI (English) Presentation Material: (J.P. Morgan Healthcare Conference: 1/8): ttp://v4.eir-parts.net/v4Contents/View.aspx?template=ir_material_for_fiscal_ym&sid=44192&code=4565 (1/16up)
・HTL0018318 (AD): Same Compound Being Advanced by Allergan for AD in Our Partnered Pipeline. "Phase 1b"
・HTL0018318 (DLB): Phase 2 POC Monotherapy Study, Expected to Begin in Japan in 2018. "Phase 2 Ready"
※SOSEI株主通信：戦略面では、当社ビジネス・パイプライン双方を強化する投資と交渉を完了しただけでなく、海外における資金調達においても大きな成功を収めました。(2/2)
※Allergan Q4 and FY 2017: Pipeline Highlights 2017: Muscarinic Receptor M1: Ph 1, 2H 2017 and M4 Agonist: Entry Ph 1, 2H 2017. Rspectively: "Achieved". FY 2017 R&D Milestones: $15m.(2/6)
※SOSE決算：研究開発費3,456百万円(48.4％増加)97.1%は英国活動。日本におけるHTL0018318(DLB)の臨床試験開始に向けた準備を含め、自社独自のパイプライン拡大に向けた投資も継続増加。(2/14)
※Allergan : Management's and Analysis. Long-term Obligations: Heptares Transaction: (Maximum Milestones: $ 3,224.5m, R&D / Approval: $ 649.5m, Sales Based and Other Milestones: $ 2,575m). (2/16)
※ClinicalTrial: A Phase 1b, Multi-center Study to Determine the Safety and Tolerability of HTL0018318 in Subjects With Alzheimer's Disease Receiving Standard-of-care: New Trial Record. Ph1b. (3/7up)
・Detailed Description: NCT03456349 (Protocol ID: HTL0018318-202):
・This is a multi-centre study conducted in four countries (Locations: Czechia: Recruiting, Poland: Recruiting, Slovakia: Recruiting, Spain: Recruiting.).
・A total of 60 subjects with Alzheimer's disease who are on standard-of-care will be enrolled to receive one of 3 active HTL0018318 or placebo for a period of four weeks.
・Actual Study Start Date: 2017/11/10. (First Posted: 2018/3/7 (Key Record Dates).
・Estimated Study Completion Date: 2018/8.
・・・
※SOSEI個人投資家説明会：Richard Henderson博士ノーベル化学賞受賞記念講演、日本における第2相臨床試験の準備が進行中のHTL0018318を含むパイプラインの進捗状況を発表。(3/14)
・・・ ※SOSEIの成長相場の動向：成長戦略の進捗と共に予定通りに推移。笑。
2014/_4/25 (終値_2058) 売残高36200 買残高 1053200 ・(2014/4/22最安値_1854)※[成長回収期の入口]ステージへ
2015/_2/20 (終値_3780) 売残高14200 買残高 1530800 ・(2015/3/16最安値_2851)※Heptares [成功の序章ステージ]
2015/10/30 (終値_4320) 売残高11400 買残高 2217900 ・(2015/9/24安値_3550)※米国承認[次なる飛躍ステージへ]
2015/11/27 (終値_6360) 売残高 14800 買残高 2552500 ・(2015/11/30終値_6060: Pfizer)※[上抜け圏へ]
2016/_4/25 (終値23230) 売残高39800 買残高 3404900 ・(2016/5/9最高値26180)※Allergan[強気相場]
2016/_6/24 (終値14720) 売残高10500 買残高 2486100 ・(2016/6/24安値12960)※[強気相場解除]→※[時間軸での調整局面へ]
2017/_1/_6 (終値14030) 売残高__300 買残高 2907100 ・(2017/2/13安値12400)※[強気相場解除後の時間軸調整は順調に推移]
2017/_3/31 (終値10880) 売残高_5600 買残高 2621800 ・(2017/4/4安値10280)※[振るい場・拾い場へ]
2017/_9/_8 (終値_8700) 売残高_1900 買残高 2037800 ・(2017/9/6最安値_8590)※[拾い場も順調に推移]
2017/11/17 (終値12190) 売残高_3100 買残高 1532100 ・(2017/10/4安値_9090)※[時間軸調整終盤、予定通りに推移]
2018/_1/26 (終値12210) 売残高__900 買残高 1429100 ・(2017/12/6安値_9970)※[振るいも順調に推移]
2018/_3/_2 (終値_9380) 売残高10500 買残高 1854600 ・(2/6, 2/14安値_9700、2/22安値_9460、3/2安値_9270)
2018/_3/_5 (終値_8900) 5日線乖離(-6.32%) 25日線乖離(-13.26％) 75日線乖離(-17.89％) 200日線乖離(-16.66％) (安値_8780)
2018/_3/_6 (終値_9130) 5日線乖離(-2.58%) 25日線乖離(-10.09％) 75日線乖離(-15.57％) 200日線乖離(-14.42％) (安値_9060)
2018/_3/_7 (終値_9060) 5日線乖離(-2.05%) 25日線乖離(_-9.83％) 75日線乖離(-15.99％) 200日線乖離(-14.98％) (安値_9000)
2018/_3/_8 (終値_9400) 5日線乖離(+2.46%) 25日線乖離(_-5.55％) 75日線乖離(-12.61％) 200日線乖離(-11.71％) (安値_9100) ・(3/5安値_8780)
更なる成長の黎明期、上抜け圏にて、強気相場解除後の時間軸での調整(振るい)は順調に推移。笑。
時間軸調整終盤、予定通りに推移し、悪地合いにて再びの拾い場、面白くなりました。笑。
成長戦略の進捗と共に、次なる展開・進捗が楽しみです。笑。 >>87
で、小学生レベルの動機で買わずに今日に至る私がここに居ますって事かいw https://www.clinicaltrials.gov/ct2/show/NCT03456349
これ１相だけど患者投与なんですね。場所はヨーロッパ各地。ようやくアラガンが動き出したということですね。 >>93
ちょw
何言いたいのか分からない
自分のレス読み直してみなよw
羞恥心くらい持とうなww ※Journal of Medicinal Chemistry: Structure Based Optimization Strategies for G Protein-Coupled Receptor (GPCR) Allosteric Modulators: A Case Study from Analyses of New Metabotropic Glutamate Receptor 5 (mGlu5) X-ray structures. (Publication 2/18up)
※Heptares: Our Most Recent Publication "Structure Based Optimization Strategies for GPCR Allosteric Modulators: A Case Study from Analyses of New mGlu5 X-ray structures." (2/22)
↓
※RCSB Protein Data Bank: "Crystal Structure of mGluR5: 6FFH, 6FFI." (Released 3/7)
・6FFH: Crystal Structure of mGluR5 in complex with Fenobam at 2.65 A. (Released: 2018-03-07. Deposited: 2018-01-08.)
・6FFI: Crystal Structure of mGluR5 in complex with MMPEP at 2.2 A. (Released: 2018-03-07. Deposited: 2018-01-08.)
(Literature: Structure Based Optimization Strategies for G Protein-Coupled Receptor (GPCR) Allosteric Modulators: A Case Study from Analyses of New Metabotropic Glutamate Receptor 5 (mGlu5) X-ray structures.)
ちなみに
※Heptares_HP: Press room Downloads page (3/8 Delete) >>106
4,000円台で売ったお寿司、ミノルタ、ハゲ喜代司にとっての適正価格ｗ 後期第一相だとマイル入らんよな
ま、進捗なら十分安心材料だが 次なる飛躍へ。着実な進捗と共に更なる成長の黎明期にて振るい育ちゆく相場。控える材料と共に水準訂正。笑。
成長期。予定されていた業績の急成長と共に更なる成長戦略が進展。順調なR&D・PL等の拡充・拡大の加速。笑。
Heptares is Currently Based in Welwyn Garden City but will be Moving to a brand New Research Facility at Granta Park (Cambridge) in July 2018.
Heptares has been Operating Approximately 130 Employees who will all be based in this New Research Facility.
・・・
※Pluristem Quarterly Report: "Our Expectations; Sosei CVC for the clinical development and commercialization of Pluristem’s PLX-PAD cell therapy product in Japan." (2/7)
※Pluristem: Issues Letter to Shareholders: "Pluristem is working hard to negotiate the best possible terms for a Japanese JV and will provide an update upon reaching an agreement." (2/7)
※SOSEI：AstraZeneca社とのがん免疫療法分野の共同開発プログラムが順調に進行。後期第I相試験が開始。2019年後半に完了する予定。2018年第1四半期に新規併用療法臨床試験を開始予定。(2/8)
※ペプチドリーム決算：Heptares戦略的提携、この共同研究では、両社のもつ業界屈指のプラットフォーム技術を集結。両社での取組みは着実に進んでおり、近く進捗状況の報告が提供できる。(2/13)
※SOSE決算：研究開発費3,456百万円(48.4％増加)97.1%は英国活動。通期予想：売上収益に関する見通しを若干修正。現金収入はブレイク・イーブンから7百万米ドル損失の範囲となる見込み。(2/14)
※SOSEI：ウルティブロ投与治療により肺過膨張を伴うCOPD罹患患者の心臓機能及び肺機能が大幅に改善。2剤配合気管支拡張薬が心臓機能へ与える影響を調査した初めての試験(CLAIM)。(2/22)
※日本商標出願(Sosei)：SOSeIHEPTARES (https://pbs.twimg.com/media/DXNlWr8UMAAQbNa.jpg) 出願日:2018/2/9、出願人:そーせいグループ株式会社 (2/27公開)
※Business Weekly Cambridge: Granta Park’s owner BioMed Realty: "The next move for Granta Park will be to welcome life science company Heptares in the summer". (3/2)
※Metrion Biosciences (Granta Park): Announced it has appointed "Dr Barry Kenny (Non-Executive Director.)" to its Board of Directors. "Dr Kenny is Chief Business Officer of Heptares, now part of Sosei Group." (3/5)
※JITSUBO：インドNeulandとの包括的パートナーシップに向けた覚書締結。日本の先端技術とインドの高い製造能力・豊富な実績の国際連携で、大きなシナジーを創出できると確信しております。(3/5)
※四季報Online：【四季報先取り新興株50】そーせいグループ (3/7 17:05up、四季報3/16更新予定)
【開発負担】アラガン社からの巨額契約一時金剥落。旺盛な研究開発費用増重い。営業外に為替差損。19年3月期は開発進捗でロイヤルティ、開発マイルーストンは着実増。が、研究開発費増勢で利益回復限定的。
【自社パイプライン】他社との提携・導出に加え、自社販売視野に入れた開発候補７品目保有。18年内にレビー小体型認知症薬は2相、神経性疾患薬は1相入り目指す。 ※ClinicalTrial(Protocol ID: HTL0018318-202): A Phase 1b, Multi-center Study to Determine the Safety and Tolerability of HTL0018318 in Subjects With AD. Actual Start: 2017/11/10. Estimated Completion: 2018/8. (New Trial Record 3/7up)
※RCSB Protein Data Bank: "Crystal Structure of mGluR5 in complex: 6FFH(with Fenobam at 2.65 A), 6FFI(with MMPEP at 2.2 A)." (Released 3/7)
※Heptares_HP: Press room Downloads page (3/8 Delete)
・・・
※MorphoSys Publication of Year-End 2017 Results. (3/13)
※Heptares: We are now recruiting for a "Cryo-Electron Microscopy Scientist" to join our biophysics group GPCR. (3/13 Closing)
※SOSEI個人投資家説明会(Richard Henderson博士ノーベル化学賞受賞記念講演、日本における第2相臨床試験の準備が進行中のHTL0018318を含むパイプラインの進捗状況を発表)：当社株主対象 (3/14 10:00)
※Imperial College London: Recruit a "Research Associate" to join the research programme in Imperial Heptares project, which focuses on the "Role of GPCRs in gastrointestinal physiology". (3/14 Closing)
※Heptares: We are now seeking a skilled "Computational Chemist" to Join the computational chemist team GPCR. (3/15 Closing)
※名古屋大学細胞生理学研究センター/株式会社CeSPIA：『Richard Henderson博士による講演会』："Electron cryomicroscopy in structural biology: progress and prospects." Richard Henderson. (3/16 14:00)
※The Cambridge Science Festival 2018: University of Cambridge: Cambridge Academy for Science and Technology: "Revealing the wonders of the molecular world": Richard Henderson. (3/20 18:00)
※ACS Symposium: "Unmasking full GPCR ligand design for potency, selectivity and kinetics from new and multiple ligand X-ray structures, water networks and GRID molecular interaction field analyses": Jon Mason. (3/21 9:35)
※Vectura Preliminary Results for the 12-months ended 31 December 2017. (3/21)
※Biotech and Money: Biotechs and the City Spring 2018, London: Panel: "Changing trends in life science deals". Panellist: Malcolm Weir, Chairman and CEO, Heptares. (3/22 18:40)
※Heptares: We are currently seeking a highly motivated and skilled organic chemist to join the Medicinal Chemistry Team as a Research Scientist; Post-Doctoral, One-Year Fixed Term Position. (4/3 Closing)
※Heptares: We are growing our established Medicinal Chemistry Team and are seeking an enthusiastic and motivated Scientist with Synthetic Organic Chemistry; One-Year Fixed Term Position. (4/3 Closing)
※MiNA Therapeutics: Seeking two highly motivated and talented "Senior Technicians" to join its research team developing novel therapeutics in the field of RNA activation. (4/17 Closing)
・・・ ※SOSEIの成長相場の動向：成長戦略の進捗と共に予定通りに推移。笑。
2010/12/30 (終値_1350) ・(2010/10/15※最安値_650、2010/12/27最高値_1748)
2011/12/30 (終値_1271) ・(2011/3/15※最安値__693、2011/6/30最高値_1680)
2012/12/28 (終値_2087) ・(2012/6/6※最安値__950、2012/9/7最高値_2967)
2013/12/30 (終値_4315) ・(2013/1/4※最安値_2050、2013/5/7最高値_6100)
2014/_4/25 (終値_2058) 売残高36200 買残高 1053200 ・(2014/4/22最安値_1854)※[成長回収期の入口]ステージへ
2015/_2/20 (終値_3780) 売残高14200 買残高 1530800 ・(2015/3/16最安値_2851)※Heptares [成功の序章ステージ]
2015/10/30 (終値_4320) 売残高11400 買残高 2217900 ・(2015/9/24安値_3550)※米国承認[次なる飛躍ステージへ]
2015/11/27 (終値_6360) 売残高 14800 買残高 2552500 ・(2015/11/30終値_6060: Pfizer)※[上抜け圏へ]
2016/_4/25 (終値23230) 売残高39800 買残高 3404900 ・(2016/5/9最高値26180)※Allergan[強気相場]
2016/_6/24 (終値14720) 売残高10500 買残高 2486100 ・(2016/6/24安値12960)※[強気相場解除]→※[時間軸での調整局面へ]
2017/_1/_6 (終値14030) 売残高__300 買残高 2907100 ・(2017/2/13安値12400)※[強気相場解除後の時間軸調整は順調に推移]
2017/_3/31 (終値10880) 売残高_5600 買残高 2621800 ・(2017/4/4安値10280)※[振るい場・拾い場へ]
2017/_9/_8 (終値_8700) 売残高_1900 買残高 2037800 ・(2017/9/6最安値_8590)※[拾い場も順調に推移]
2017/11/17 (終値12190) 売残高_3100 買残高 1532100 ・(2017/10/4安値_9090)※[時間軸調整終盤、予定通りに推移]
2018/_1/26 (終値12210) 売残高__900 買残高 1429100 ・(2017/12/6安値_9970)※[振るいも順調に推移]
2018/_3/_2 (終値_9380) 売残高10500 買残高 1854600 ・(2/6, 2/14安値_9700、2/22安値_9460、3/2安値_9270)
2018/_3/_8 (終値_9400) 5日線乖離(+2.46%) 25日線乖離(-5.55％) 75日線乖離(-12.61％) 200日線乖離(-11.71％) (安値_9100) ・(3/5安値_8780)※[悪地合いにて再びの拾い場]
・Technical Analysis Charts (Week)：
ttps://www.zonebourse.com/zbcache/charts/ObjectChart.aspx?Name=6814799&Type=Custom&Intraday=1&Width=980&Height=650&Cycle=WEEK1&Duration=120&TopMargin=10&Render=Candle&ShowName=0&Company=4Traders_us
更なる成長の黎明期、上抜け圏にて、強気相場解除後の時間軸での調整(振るい)は順調に推移。笑。
時間軸調整終盤、予定通りに推移し、悪地合いにて再びの拾い場、面白くなりました。笑。
成長戦略の進捗と共に、次なる展開・進捗が楽しみです。笑。 ※MiNA Therapeutics 1時間前: Small step up to 1st floor at the I-Hub (ThinkSpace London). (3/9)
https://pbs.twimg.com/media/DXy-sSJWsAAEg18.jpg:large
Imperial College London White City Incubator: Offices in the Translation & Innovation Hub (I-HUB):
・The Translation & Innovation Hub (I-HUB) is located in the Northern half of Imperial College White City Campus, can accommodate office and laboratory use by scientific companies.
・The first floor of the I-HUB provides fully furnished private offices from 250sq ft, offered in combination with fitted wet lab facilities.
・The second and third floors are offered as shell and core.
・Co-working spaces are provided by Central Working White City on the fourth floor.
・The fifth to eleventh floors provide office accommodation completed to CAT A specification from 8,000 sq ft. トランプ米大統領が北朝鮮の金委員長からの書簡受け取る＝CNN
きたああああああああああああああああああああああああああああああああああああああああああああああ ナノキャリア早朝のIP
効果ナシわろた
アキュセラの再来ｗ さて
ナノキャリアの気配おかずに朝食の支度するか！ どうしたそーせいやる気出したか？
まあ今更やる気だしたところで12000までは全く届かないところだけどな >>137
でも12000円から3000円も下がったぞ？ この地合いでマイ転するようなクソ株だと思ってんの？ 昼休みに先物マイ転からの雇用統計でブラマンあるでこれ 今日一度もマイテンしてないのにルサンチメンズ風説流し過ぎｗ この地合いならマイ転でもしゃーないな
今夜は波乱か 来週水曜日の説明会に行く予定だけど、会終了後の懇親会はないんですよね？ 簡単な立食を用意していますので時間の許す株主様はどうぞ、なんてことはないか FX（外国為替証拠金取引）のEA(自動売買ツール)を開発・公開しております。
興味がありましたら見てみてください。
http://qawsedr5tyu12345678.ldblog.jp/archives/7206121.html そんな時間与えずさっさと帰りたいだろう
株価について突っ込まれること必至なんだし きゅうり大好きふきのとう婆さんは今月大損こいてスレ荒らしもおやすみｗｗｗ ※MiNA Therapeutics 7分前: New paper published in Oncogene describing impressive efficacy of MTL-CEBPA drug candidate in animal models of liver disease. MTL-CEBPA currently being tested in OUTREACH clinical trial in liver cancer patients.
※MiNA Therapeutics: Announces Publication of Pre-Clinical Data Supporting Therapeutic Potential of Clinical Candidate MTL-CEBPA in Liver Cancer and Liver Disease.
--Data Published in Oncogene Demonstrate Improvement of Liver Function and Increased Survival in Multiple Disease Models--
March 09, 2018 05:00 AM Eastern Standard Time
LONDON--(BUSINESS WIRE)--MiNA Therapeutics, the pioneer in RNA activation therapeutics,
today announced the publication of pre-clinical data on its MTL-CEBPA program in which the compound was shown to promote disease reversal in several models of liver disease and to reduce tumour burden in a model of liver cancer.
MTL-CEBPA consists of CEBPA-51 small activating RNAs encapsulated in SMARTICLES® nanoparticles.
It is the first development candidate to emerge from MiNA’s RNA activation platform and is currently being evaluated in a Phase I clinical study in patients with liver cancer.
The data underscore the potential of this compound to address both severe liver disease indications as well as earlier disease stages to enhance chances of survival.
“The combination of beneficial effects observed across a range of liver disease models supports a unique and promising role for MTL-CEBPA therapy in the treatment of liver diseases and liver cancer,”
commented Robert Habib, CEO of MiNA Therapeutics.
“This exciting pre-clinical data highlights the potential of saRNAs to up-regulate gene expression and treat disease in radically new ways compared to conventional medicines.”
In the publication, researchers investigated the potential benefits of MTL-CEBPA in a set of in vivo severe liver disease models representing advanced liver cirrhosis, non-alcoholic steatohepatitis (NASH) and liver cancer.
Overall, MTL-CEBPA was shown to restore the expression of CEBPA, a master regulator of liver function. In the advanced liver cirrhosis model,
MTL-CEBPA significantly reversed liver fibrosis and liver dysfunction and enhanced survival. In a model of NASH, MTL-CEBPA reversed liver steatosis.
Improved liver function as well as a large reduction in tumour burden was also seen in a model of primary liver cancer.
Together, these findings validate the beneficial role of up-regulating CEBPA expression in liver disease and liver cancer and are consistent with externally published data using genetic models of liver disease.
The publication titled “Gene activation of CEBPA using saRNA: Preclinical studies of the first in human saRNA drug candidate for liver cancer”,
was published in the latest issue of Oncogene by researchers at MiNA Therapeutics in collaboration with several well-regarded academic institutions including scientists at Imperial College London and National Taiwan University Hospital.
The paper is available on the Company’s website in the publications section under “Media”. ※MiNA Therapeutics 10分前: Read our new preclinical paper on MTL-CEBPA in Oncogene journal.
※Oncogene: Gene activation of CEBPA using saRNA: preclinical studies of the first in human saRNA drug candidate for liver cancer.
Published online: 07 March 2018
Abstract
Liver diseases are a growing epidemic worldwide. If unresolved, liver fibrosis develops and can lead to cirrhosis and clinical decompensation.
Around 5% of cirrhotic liver diseased patients develop hepatocellular carcinoma (HCC), which in its advanced stages has limited therapeutic options and negative survival outcomes.
CEPBA is a master regulator of hepatic function where its expression is known to be suppressed in many forms of liver disease including HCC.
Injection of MTL-CEBPA, a small activating RNA oligonucleotide therapy (CEBPA-51) formulated in liposomal nanoparticles (NOV340- SMARTICLES) upregulates hepatic CEBPA expression.
Here we show how MTL-CEBPA therapy promotes disease reversal in rodent models of cirrhosis, fibrosis, hepatosteatosis, and significantly reduces tumor burden in cirrhotic HCC.
Restoration of liver function markers were observed in a carbon-tetrachloride-induced rat model of fibrosis following 2 weeks of MTL-CEBPA therapy.
At 14 weeks, animals showed reduction in ascites and enhanced survival rates.
MTL-CEBPA reversed changes associated with hepatosteatosis in non-alcoholic methionine and cholic-deficient diet-induced steaotic liver disease.
In diethylnitrosamine induced cirrhotic HCC rats, MTL-CEBPA treatment led to a significant reduction in tumor burden.
The data included here and the rapid adoption of MTL-CEBPA into a Phase 1 study may lead to new therapeutic oligonucleotides for undruggable diseases.
https://www.nature.com/articles/s41388-018-0126-2 次なる飛躍へ。着実な進捗と共に更なる成長の黎明期にて振るい育ちゆく相場。控える材料と共に水準訂正。笑。
成長期。予定されていた業績の急成長と共に更なる成長戦略が進展。順調なR&D・PL等の拡充・拡大の加速。笑。
Heptares is Currently Based in Welwyn Garden City but will be Moving to a brand New Research Facility at Granta Park (Cambridge) in July 2018.
Heptares has been Operating Approximately 130 Employees who will all be based in this New Research Facility.
・・・
※米国特許(MiNA)：Methods of Inducing Insulin Production. (2/6公開)
※Pluristem Quarterly Report: "Our Expectations; Sosei CVC for the clinical development and commercialization of Pluristem’s PLX-PAD cell therapy product in Japan." (2/7)
※Pluristem: Issues Letter to Shareholders: "Pluristem is working hard to negotiate the best possible terms for a Japanese JV and will provide an update upon reaching an agreement." (2/7)
※SOSEI：AstraZeneca社とのがん免疫療法分野の共同開発プログラムが順調に進行。後期第I相試験が開始。2019年後半に完了する予定。2018年第1四半期に新規併用療法臨床試験を開始予定。(2/8)
※ペプチドリーム決算：Heptares戦略的提携、この共同研究では、両社のもつ業界屈指のプラットフォーム技術を集結。両社での取組みは着実に進んでおり、近く進捗状況の報告が提供できる。(2/13)
※SOSE決算：研究開発費3,456百万円(48.4％増加)97.1%は英国活動。通期予想：売上収益に関する見通しを若干修正。現金収入はブレイク・イーブンから7百万米ドル損失の範囲となる見込み。(2/14)
※MiNA Therapeutics: Seeking two highly motivated and talented "Senior Technicians" to join its research team developing novel therapeutics in the field of RNA activation. "4/17 Closing" (2/16up)
※RNA Therapeutics Conference, London: "Utilising Small Activating RNA (saRNA) for Therapeutic Opportunities": Nagy Habib, Chairman and Co-Founder, MiNA Therapeutics. (2/21)
※SOSEI：ウルティブロ投与治療により肺過膨張を伴うCOPD罹患患者の心臓機能及び肺機能が大幅に改善。2剤配合気管支拡張薬が心臓機能へ与える影響を調査した初めての試験(CLAIM)。(2/22)
※日本商標出願(Sosei)：SOSeIHEPTARES 出願日:2018/2/9、出願人:そーせいグループ株式会社 (2/27公開)
※欧州特許出願(MiNA)：C/EBP Alpha Sarna Compositions and Methods of Use. (2/28公開)
※欧州特許出願(MiNA)：Sarna Compositions and Methods of Use. (2/28公開) ※MiNA Therapeutics: Read about Our CEO Robert Habib in an Interview with OTS(Oligonucleotide Therapeutics Society). (3/2)
※Business Weekly Cambridge: Granta Park’s owner BioMed Realty: "The next move for Granta Park will be to welcome life science company Heptares in the summer". (3/2)
※Metrion Biosciences (Granta Park): Announced it has appointed "Dr Barry Kenny (Non-Executive Director.)" to its Board of Directors. "Dr Kenny is Chief Business Officer of Heptares, now part of Sosei Group." (3/5)
※JITSUBO：インドNeulandとの包括的パートナーシップに向けた覚書締結。日本の先端技術とインドの高い製造能力・豊富な実績の国際連携で、大きなシナジーを創出できると確信しております。(3/5)
※米国特許(Heptares)：Muscarinic M1 Receptor Agonists. (3/6公開)
※四季報先取り：旺盛な研究開発費用増重い。利益回復限定的。他社との提携・導出に加え、自社販売視野に入れた開発候補７品目保有。18年内にレビー小体型認知症薬は2相、神経性疾患薬は1相入り目指す。(3/7)
※Nature.com: Oncogene: "Gene activation of CEBPA using saRNA: preclinical studies of the first in human saRNA drug candidate for liver cancer." (3/7)
※ClinicalTrial(HTL0018318-202): A Phase 1b, Multi-center Study to Determine the Safety and Tolerability of HTL0018318 in Subjects With AD. Actual Start: 2017/11/10. Estimated Completion: 2018/8. (New Trial Record 3/7up)
※RCSB Protein Data Bank: "Crystal Structure of mGluR5 in complex: 6FFH(with Fenobam at 2.65 A), 6FFI(with MMPEP at 2.2 A)." (Released 3/7up)
※MiNA Therapeutics: Small Step Up to 1st Floor at the Translation & Innovation Hub (Imperial College London White City Campus). (3/8)
※MiNA Therapeutics: Announces Publication of Pre-Clinical Data Supporting Therapeutic Potential of Clinical Candidate MTL-CEBPA in Liver Cancer and Liver Disease. (3/9)
http://minatx.com/news/mina-therapeutics-announces-publication-of-pre-clinical-data-supporting-therapeutic-potential-of-clinical-candidate-mtl-cebpa-in-liver-cancer-and-liver-disease/
・・・
※SOSEI個人投資家説明会：Richard Henderson博士ノーベル化学賞受賞記念講演、日本における第2相臨床試験の準備が進行中のHTL0018318を含むパイプラインの進捗状況を発表。(3/14)
・・・ ※SOSEIの成長相場の動向：成長戦略の進捗と共に予定通りに推移。笑。
2017/_1/_6 (終値14030) 売残高__300 買残高 2907100 ・(2017/2/13安値12400)※[強気相場解除後の時間軸調整は順調に推移]
2017/_3/31 (終値10880) 売残高_5600 買残高 2621800 ・(2017/4/4安値10280)※[振るい場・拾い場へ]
2017/_9/_8 (終値_8700) 売残高_1900 買残高 2037800 ・(2017/9/6最安値_8590)※[拾い場も順調に推移]
2017/11/17 (終値12190) 売残高_3100 買残高 1532100 ・(2017/10/4安値_9090)※[時間軸調整終盤、予定通りに推移]
2017/12/_8 (終値10100) 売残高__900 買残高 1849800 ・(2017/12/6安値_9970)
2018/_1/26 (終値12210) 売残高__900 買残高 1429100(-214600) ・(1/22安値10960)※[振るいも順調に推移]
2018/_2/_2 (終値11650) 売残高__300 買残高 1482300(_+53200) ・(1/31安値11440)
2018/_2/_9 (終値10330) 売残高12500 買残高 1524700(_+42400) ・(2/6安値_9700)
2018/_2/16 (終値_9920) 売残高11800 買残高 1591200(_+66500) ・(2/14安値_9700)
2018/_2/23 (終値_9620) 売残高_9800 買残高 1773800(+182600) ・(2/22安値_9460)
2018/_3/_2 (終値_9380) 売残高10500 買残高 1854600(_+80800) ・(3/2安値_9270)
2018/_3/_5 (終値_8900) 5日線乖離(-6.32%) 25日線乖離(-13.26％) 75日線乖離(-17.89％) 200日線乖離(-16.66％) (安値_8780)※[悪地合いにて再びの拾い場]
2018/_3/_6 (終値_9130) 5日線乖離(-2.58%) 25日線乖離(-10.09％) 75日線乖離(-15.57％) 200日線乖離(-14.42％) (安値_9060)
2018/_3/_7 (終値_9060) 5日線乖離(-2.05%) 25日線乖離(_-9.83％) 75日線乖離(-15.99％) 200日線乖離(-14.98％) (安値_9000)
2018/_3/_8 (終値_9400) 5日線乖離(+2.46%) 25日線乖離(_-5.55％) 75日線乖離(-12.61％) 200日線乖離(-11.71％) (安値_9100)
2018/_3/_9 (終値_9510) 5日線乖離(+3.37%) 25日線乖離(_-3.49％) 75日線乖離(-11.33％) 200日線乖離(-10.61％) (安値_9400)
更なる成長の黎明期、上抜け圏にて、強気相場解除後の時間軸での調整(振るい)は順調に推移。笑。
時間軸調整終盤、予定通りに推移し、悪地合いにて再びの拾い場、面白くなりました。笑。
成長戦略の進捗と共に、次なる展開・進捗が楽しみです。笑。 ※HeptaresTL 25分前: We are now seeking to recruit a highly motivated Analytical / Separation Scientist (Scientist/Research Scientist Grade). (3/9)
※Heptares Therapeutics: "Analytical / Separation Scientist (Scientist/Research Scientist Grade)" (3/9up)
Company Description:
Heptares Therapeutics is an established UK biotech company with world-class technology in structure-based drug design applied to discovery of novel small molecules acting through GPCRs.
The company is developing its own pipeline of proprietary molecules, and works in collaboration with major global pharmaceutical companies on both small molecule and antibody discovery programmes.
The most advanced of these are now in clinical studies with others moving towards clinical development.
The company is currently based in Welwyn Garden City but will be moving to a brand new research facility at Granta Park (Cambridge) in July 2018.
Heptares has been operating for over ten years and has approximately 130 employees who will all be based in this new research facility.
The size of the company ensures a transparent linkage between all activities from early discovery through to clinical development.
Position:
As a result of the increased activities in building our own pipeline we now seek to recruit a highly motivated analytical chemist
to join the analytical and compound purification team within our medicinal chemistry department.
The individual should have a relevant background in analytical chemistry and preferably experience of state-of-the-art reverse phase purification systems.
The candidate should be flexible and be able to adapt to meet team requirements.
The role will involve both analytical and preparative separation aspects within our HPLC, UPLC-MS and SFC-MS capabilities.
In addition to this, the individual will help support our compound/ sample quality control as part of the overall compound management process.
The successful candidate would receive full training in the specific systems used at Heptares.
For the right candidate, the role provides an opportunity to work with senior scientists to develop
and apply best practice in a rapidly growing company on scientifically challenging issues at the cutting edge of discovery and development of new medicines.
Requirements
We are seeking candidates whose profiles will include:
1. a minimum 2.1 degree in Analytical Chemistry (or closely related discipline)
2. relevant experience is desirable but not essential; comprehensive training will be provided;
3. being highly motivated and enthusiastic to learn new skills and techniques to contribute to the ongoing discovery research;
4. being proactive and responsive to the challenges of the role, working within the broader medicinal chemistry department;
5. excellent communication and interaction skills and demonstrated capability to operate in a proactive, collaborative and entrepreneurial biotech culture; and,
6. being able to clearly communicate both verbally and in written reports in English.
The closing date for applications is 3rd April 2018. ・・・
※Heptares: We are now recruiting for a "Cryo-Electron Microscopy Scientist" to join our biophysics group GPCR. (3/13 Closing)
※Imperial College London: Recruit a "Research Associate" to join the research programme in Imperial Heptares project, which focuses on the "Role of GPCRs in gastrointestinal physiology". (3/14 Closing)
※Heptares: We are now seeking a skilled "Computational Chemist" to Join the computational chemist team GPCR. (3/15 Closing)
※Heptares: We are currently seeking a highly motivated and skilled organic chemist to join the Medicinal Chemistry Team as a Research Scientist; Post-Doctoral, One-Year Fixed Term Position. (4/3 Closing)
※Heptares: We are growing our established Medicinal Chemistry Team and are seeking an enthusiastic and motivated Scientist with Synthetic Organic Chemistry; One-Year Fixed Term Position. (4/3 Closing)
※Heptares: We are now seeking to recruit a highly motivated "Analytical / Separation Scientist (Scientist/Research Scientist Grade)" GPCR. (4/3 Closing) : (3/9up)
※MiNA Therapeutics: Seeking two highly motivated and talented "Senior Technicians" to join its research team developing novel therapeutics in the field of RNA activation. (4/17 Closing) ※Peter Nollert 9時間前: Structural perspective on small molecule allosteric sites in GPCRs. (3/9)
ttps://pbs.twimg.com/media/DX2WZJlWkAArKN6.jpg
※Journal of Medicinal Chemistry: Small Molecule Allosteric Modulators of G-Protein-Coupled Receptors: Drug–Target Interactions.
・Publication Date (Web): February 19, 2018.
Abstract
Abstract Image: ttps://pubs.acs.org/appl/literatum/publisher/achs/journals/content/jmcmar/0/jmcmar.ahead-of-print/acs.jmedchem.7b01844/20180226/images/medium/jm-2017-018448_0025.gif
G-protein-coupled receptors (GPCRs) are the largest class of signaling receptors that are most frequently targeted by therapeutic drugs.
Allosteric modulators bound to GPCRs at allosteric sites provide the potential for differential selectivity and improved safety compared with traditional orthosteric ligands.
The recent breakthroughs in GPCR structural biology have made structures of GPCRs from classes A, B, C, and F complexed with small-molecule allosteric modulators available.
Knowledge of the detailed receptor–modulator interactions at the allosteric sites is useful for structure-based GPCR drug design of novel therapeutics.
This Perspective comprehensively summarizes the current status of structural complexes between GPCRs and their small-molecule allosteric modulators,
particularly the key receptor–modulator interactions at the allosteric sites.
Then, the structural diversity of allosteric sites across four GPCR subfamilies is compared.
This study is expected to contribute to the design of GPCR allosteric drugs with an improved therapeutic action.
Primary Data (Heptares):
・5NDZ: Crystal structure of a thermostabilised human protease-activated receptor-2 (PAR2) in complex with AZ3451 at 3.6 angstrom resolution
・5EE7: Crystal structure of the human glucagon receptor (GCGR) in complex with the antagonist MK-0893
・4OO9: Structure of the human class C GPCR metabotropic glutamate receptor 5 transmembrane domain in complex with the negative allosteric modulator mavoglurant
・5CGD: Structure of the human class C GPCR metabotropic glutamate receptor 5 transmembrane domain in complex with the negative allosteric modulator 3-chloro-5-[6-(5-fluoropyridin-2-yl)pyrimidin-4-yl]benzonitrile - (HTL14242)
・5LWE: Crystal structure of the human CC chemokine receptor type 9 (CCR9) in complex with vercirnon 病人に何言っても変わらんよ
アク禁とか書き込み禁止になるまでずーっと続ける あれ、売り煽り君たち、chiさんがMiNAの超絶材料を書き込んだからってそんなこと言うのやめなよー(о´∀`о)
どう考えてもそーせいは割安。そのうち爆発するのは目に見えてるよ💣 そーせいがお知らせで出してない以上全く意味をなさない情報だが >>177
MiNA Therapeutics Announces Publication of Pre-Clinical Data Supporting Therapeutic Potential of Clinical Candidate MTL-CEBPA in Liver Cancer and Liver Disease 英語で何かいてあるかほとんどわからんw
そーせいIRよ日本語訳頼むわw >>179
これは凄すぎる！
来週からは連続S高間違いなし！
5月連休前には間違いなく3万超えます！
神様ありがとう ■ このスレッドは過去ログ倉庫に格納されています
